30 results about "AMBROXOL HYDROCHLORIDE" patented technology

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to an ambroxol hydrochloride-containing oral liquid and application thereof, and the ambroxol hydrochloride oral liquid is composed of ambroxol hydrochloride, ligustrazine, meglumine, dextran 40, xylitol, carboxymethylcellulose, L-tryptophan, stevioside and purified water. The ligustrazine and the ambroxol hydrochloride play a synergistic effect, and the meglumine and the dextran 40 are combined for use, so that the stability of the ambroxol hydrochloride is improved. Accelerated experiments show that the ambroxol hydrochloride is stable in property and suitable for further industrial mass production.

The present invention relates to the field of pharmaceutical preparations, and particularly to an ambroxol hydrochloride solution, a preparation method thereof and an application thereof. In the present invention, diethylenetriaminepentaacetic acid is used as a stabilizer component of the ambroxol hydrochloride solution in a relatively small amount. Diethylenetriaminepentaacetic acid has strong coordination ability and can interact with other molecules in the solution, thereby greatly improving the stability of the ambroxol hydrochloride solution. The preparation method provided by the present invention is simple and easy to operate, does not require a light-proof environment, has low production cost, and is easy to industrialize. When the ambroxol hydrochloride solution provided by the present invention is used alone or applied to an inhalation preparation, no preservative component needs to be added, the quality is reliable, the safety is good, and it is more suitable for clinical use requirements.

The invention relates to the technical field of cell separation and extraction, and provides a method for extracting extracellular vesicles from induced sputum. Comprising the following steps: S1, atomizing and collecting induced sputum, picking out sputum plugs, and adding an isotonic phosphate buffer solution which contains 0.1 wt% of drocisteine and 0.1 wt% of tween-20 and has the pH value of 6.0 for dissolving, so as to obtain an induced sputum dissolving solution rich in extracellular vesicles; wherein the dissolving temperature is 37 + / -0.1 DEG C, and digestion is performed for 15 + / -1 min under the condition that the rotating speed of a shaking table is 50 + / -1 rpm; and S2, extracting the extracellular vesicles from the induced sputum dissolving solution through a negative pressure size exclusion chromatography method. According to the invention, the multi-component dissolving agent of the hydroxymethylsteine and the Tween-20 is adopted to promote the dissolving of sputum and protect protein and nucleic acid in extracellular vesicles from being degraded; the negative pressure size exclusion chromatography can accurately control the flow velocity driven by negative pressure, ensures stable migration of extracellular vesicles in a chromatographic column, and avoids vesicle rupture caused by too fast flow velocity or low separation efficiency caused by too slow flow velocity.

The application provides an ambroxol oral dissolving film composition, a preparation method and application thereof. The ambroxol oral dissolving film composition comprises an active drug, a film forming material and a taste masking agent, and the active drug is 2-amino-3,5-dibromo-N-(trans-4-hydroxycyclohexyl) benzylamine and / or a pharmaceutically acceptable salt thereof, for example, ambroxol hydrochloride. The ambroxol oral dissolving film composition provided by the application has the advantages of thin thickness, good taste, stable properties, immediate dissolution in the oral cavity without drinking water, and fast oral absorption speed. Moreover, the ambroxol oral dissolving film composition has the advantages of simple process, high drug loading, good drug content uniformity, and good market prospect.

The invention discloses an ambroxol hydrochloride preparation composition and a preparation method thereof, the ambroxol hydrochloride preparation composition contains hydroxyethyl cellulose, and the weight-average molecular weight of the hydroxyethyl cellulose is selected from 900000 to 1100000. By improving the prescription raw materials and the prescription process, the production equipment requirement and cost are greatly reduced while the product quality is ensured, and the preparation method is very suitable for large-scale industrial production.

The invention discloses a production process of an ambroxol oral solution, and belongs to the technical field of chemical medicinal preparations, the production process comprises the following steps: adding an aqueous solution containing ambroxol hydrochloride, clenbuterol hydrochloride, sorbitol, propylene glycol, glycerol, hydroxyethyl cellulose, DL-tartaric acid and sodium benzoate into a reaction kettle, and uniformly stirring to obtain the ambroxol hydrochloride oral solution, the clenbuterol hydrochloride, the sorbitol, the propylene glycol, the glycerol, the hydroxyethyl cellulose, the DL-tartaric acid and the sodium benzoate; the preparation method comprises the following steps: preparing in a production system passivated by hydroxyethyl diamine tetraacetic acid trisodium salt, treating by a two-stage series hollow membrane contactor, and finally filling a glass bottle with a liquid medicine. According to the preparation method disclosed by the invention, on the basis of prescription adjustment without adding antioxidants such as sodium pyrosulfite and the like, the impurities of the medicine in the production and storage processes are obviously reduced, the product stability and the clinical medication safety are improved, and the preparation process is simple and stable to operate and suitable for industrial production.

The invention discloses a porous core-shell microsphere with thermosensitivity and acid responsiveness and a preparation method of the porous core-shell microsphere, and belongs to the technical field of biological medicines. The preparation method comprises the following steps: S1, carrying out a reaction on hyaluronic acid and 3, 3 '-dithiobis (propionyl hydrazide) to obtain hydrazide modified hyaluronic acid HA-TPH; s2, another part of hyaluronic acid is taken and modified with sodium periodate, and oxidized modified hyaluronic acid HA-CHO is obtained; s3, dissolving HA-TPH in water, and adding beclomethasone dipropionate to obtain a solution A; dissolving HA-CHO in water, and adding beclomethasone dipropionate to obtain a solution B; s4, the solution A and the solution B are mixed and then dropwise added into vegetable oil, and spherical gel particles are prepared through an emulsification method; s5, dissolving the shell layer material in dichloromethane, and then adding ambroxol hydrochloride and the gel particles to form an electronic injection suspension; and S6, preparing the porous core-shell microspheres by adopting a uniaxial electronic injection method. The microspheres prepared by the invention have both thermosensitivity and acid responsiveness, and the problems of inaccurate release, low utilization rate and the like of the traditional dosage form are solved.

The present application relates to the technical field of nucleic acid extraction and purification, and particularly relates to a DNA and RNA co-extraction reaction reagent and an extraction method, the reaction reagent comprising a nucleic acid protective agent RP, a sample lysis and binding liquid LB, a protein washing liquid WB1, a nucleic acid rinsing liquid WB2, and a nucleic acid elution liquid EB; the nucleic acid protective agent RP comprising DTT, mercaptoethanol, TCEP, and sodium hydroxide; the sample lysis and binding liquid LB comprising Tris-HCl, benzenesulfonic acid, sodium citrate, guanidine hydrochloride, guanidine isothiocyanate, guanidine thiocyanate, urea, triton X-100, SDS, potassium chloride, sodium chloride, bromhexine, N-acetylcysteine, ambroxol hydrochloride, isopropyl alcohol, and anhydrous ethanol; the protein washing liquid WB1 comprising Tris-HCl, benzenesulfonic acid, sodium citrate, guanidine hydrochloride, guanidine isothiocyanate, guanidine thiocyanate, urea, triton X-100, sodium chloride, isopropyl alcohol, and anhydrous ethanol; the nucleic acid rinsing liquid WB2 comprising Tris-HCl, sodium chloride, isopropyl alcohol, and anhydrous ethanol; and the nucleic acid elution liquid EB being nuclease-free water; the reagent can rapidly and fully enrich and purify DNA and RNA of a sample simultaneously.

The invention provides an ambroxterol composition and a preparation process thereof, and particularly relates to the field of medicines. Each milliliter of the liquid preparation comprises 1-2mg of ambroxol hydrochloride, 0.5-1.5 [mu] g of clenbuterol hydrochloride, 10-20mg of sodium hydrogen sulfite, 1-4mg of hydroxyethyl cellulose and purified water. The toothpaste further comprises 243-247 mg of an amorphous sorbitol solution, 3-5 mg of pomegranate essence, 148-152 mg of glycerin, 1-3 mg of sodium benzoate and a proper amount of DL-tartaric acid. According to the preparation disclosed by the invention, the increase of an impurity B can be inhibited by adding sodium hydrogen sulfite, and the increase of an ambroxol impurity 14 and an unknown single impurity can be reduced by reducing the dosage of hydroxyethyl cellulose, so that the drug stability is improved.

1. The name of the design product: packaging box (ambroxol hydrochloride oral solution). 2. The use of the design product: for product packaging. 3. The design points of the design product: in the combination of shape and pattern. 4. The picture or photo that best indicates the design points: front view.

The application provides an ambroxol oral dissolving film composition, a preparation method and application thereof. The ambroxol oral dissolving film composition comprises an active drug, a film forming material and a taste masking agent, and the active drug is 2-amino-3,5-dibromo-N-(trans-4-hydroxycyclohexyl) benzylamine and / or a pharmaceutically acceptable salt thereof, for example, ambroxol hydrochloride. The ambroxol oral dissolving film composition provided by the application has the advantages of thin thickness, good taste, stable properties, immediate dissolution in the oral cavity without drinking water, and fast oral absorption speed. Moreover, the ambroxol oral dissolving film composition has the advantages of simple process, high drug loading, good drug content uniformity, and good market prospect.

This invention relates to an ambroxol oral solution. Specifically, this invention provides an ambroxol oral solution comprising ambroxol hydrochloride, clenbuterol hydrochloride, sucralose, mannitol, trehalose, hydroxyethyl cellulose, citric acid, sodium citrate, sodium bisulfite, glycine, glycerol, and water. The ambroxol oral solution of this invention effectively improves bitterness and its residue, has an excellent taste, and also exhibits excellent stability under light, high temperature, and high humidity, thus providing excellent storage and transportation stability and ensuring quality and safety.

The invention relates to a preparation method of ambroxol hydrochloride and an intermediate thereof, in particular to a preparation method of a structure shown in a formula II and a method for further preparing ambroxol hydrochloride. The ambroxol hydrochloride is obtained by taking o-aminobenzaldehyde as an initial raw material and sequentially carrying out three-step reaction of reductive amination, bromination and salification. The preparation method provided by the invention is a brand new technical route and is not reported in any literature and patent. According to the method, the yield of the product can be greatly improved, and the method is suitable for industrial production.

The utility model discloses an ambroxol hydrochloride oral solution filtering and stirring device which comprises a stirring box, the inner wall of the stirring box is rotationally connected with a driving rod through a sealing bearing, stirring blades are installed below the outer wall of the driving rod, a feeding port is formed in the top of the stirring box, a discharging valve is installed at the bottom of the stirring box, and a discharging port is formed in the bottom of the stirring box. And a cleaning structure is arranged above the stirring blades and comprises a screen. The utility model relates to the technical field of solution production equipment, through the cooperation of a screen, a fixing plate and a supporting plate, the screen is placed between the supporting plate and a pressing plate, after the screen is installed, a driving rod is used for driving a strip box to rotate, the screen can rotate around the driving rod, and under the driving of a transmission structure, the screen can rotate, so that the production efficiency is improved. Sediments in the oral liquid are filtered in advance, and the situation that excessive sediments are accumulated on the filter screen at the bottom in the subsequent filtering process, and the filtering effect is affected is avoided.

1. The name of the design product: packaging box (ambroxol hydrochloride oral solution). 2. The use of the design product: used for the outer packaging of the product. 3. The design points of the design product: the combination of shape and pattern. 4. The picture or photo that best indicates the design points: unfolded state reference drawing.

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to an ambroxol hydrochloride oral solution and a preparation process thereof, and the preparation process comprises the following steps: heating purified water to 60-80 DEG C, adding sorbitol and L-cysteine into the purified water, stirring and dissolving for 10-30 minutes, adding hydroxyethyl cellulose, uniformly dispersing, and cooling to 48-52 DEG C to obtain a first mixed solution; adding ambroxol hydrochloride, benzoic acid and glycerol into the first mixed solution, stirring until the ambroxol hydrochloride, benzoic acid and glycerol are completely dissolved, finally adding essence, and uniformly mixing; and finally, fixing the volume to a set volume by adopting purified water. According to the preparation method disclosed by the invention, through collaborative optimization of dual effects of L-cysteine and a specific feeding sequence, even if the content of sorbitol reducing sugar is greater than 0.3%, the content of an impurity B can still be controlled to be less than or equal to 0.3%, the content of an impurity F can still be controlled to be less than or equal to 0.2%, the deviation between the content of related substances and a reference preparation is less than or equal to + / -0.3%, and the stability is excellent.

The invention relates to polydeuterated analog forms of ambroxol and related compounds (including bromhexine and the ambroxol salt, ambroxol hydrochloride), compositions comprising same, and methods of preventing and / or treating various diseases and medical conditions involving the administration of polydeuterated analogs of ambroxol and related compounds.

The invention discloses ambroxol hydrochloride syrup and a preparation process thereof, and belongs to the technical field of pharmaceutical preparations. The ambroxol hydrochloride syrup comprises ambroxol hydrochloride, a stabilizing cosolvent, a sweetening agent, a preservative, a pH regulator, essence and a solvent. Wherein the stable cosolvent is a composition of propylene glycol, meglumine and propylene carbonate, and the sweetening agent is a composition of cane sugar and a functional sweetening agent. The preparation process comprises the steps of low-temperature pretreatment of the main drug and the stable cosolvent, dissolution and mixing of the auxiliary materials, pH adjustment and essence addition, constant-volume filtration, encapsulation and the like. Through the synergistic effect of a composite stable cosolvent system and a specific preparation process, the storage stability of ambroxol hydrochloride is remarkably improved, meanwhile, the taste of the preparation is optimized, the preparation is wide in applicable crowd, the preparation process is simple and controllable, and good clinical application value and industrialization prospects are achieved.

The embodiments of this application disclose a liquid formulation, a cartridge for an aerosol generating system, and an aerosol generating system, wherein the liquid formulation comprises a solvent and ambroxol hydrochloride, and the atomization conversion rate of the ambroxol hydrochloride in the liquid formulation is 90% or more, or the atomization conversion rate of the ambroxol hydrochloride is 80% or more, or the atomization conversion rate of the ambroxol hydrochloride is 70% or more, or the atomization conversion rate of the ambroxol hydrochloride is 60% or more.

This invention proposes a compound ambroxol sustained-release microsphere and its preparation method. The compound ambroxol sustained-release microsphere comprises ambroxol hydrochloride, clenbuterol hydrochloride, and a cellulose ester sustained-release material, effectively controlling the dissolution differences between ambroxol hydrochloride and clenbuterol hydrochloride, enabling simultaneous and stable release of both drugs and avoiding efficacy fluctuations due to different release rates. Furthermore, the microsphere utilizes a hot-melt extrusion process, ensuring uniform dispersion of the two active pharmaceutical ingredients within the sustained-release material, thus resolving the uniformity issue caused by low clenbuterol hydrochloride content. The preparation process requires no organic solvents, eliminating solvent residues and preventing degradation or reactions of the active pharmaceutical ingredients in solvents, thereby improving product stability.

The present invention provides an orally disintegrating ambroxol film composition, its preparation method, and use. The orally disintegrating ambroxol film composition comprises an active drug, a film-forming material, and a flavoring agent, where the active drug is 2-amino-3,5-dibromo-N-(trans-4-hydroxycyclohexyl)benzylamine and / or its pharmacologically acceptable salt, such as ambroxol hydrochloride. The orally disintegrating ambroxol film composition according to the present invention has the advantages of being thin, pleasant to the taste, stable, instantly dissolving in the oral cavity without the need for water, and having a fast oral absorption rate. Furthermore, the orally disintegrating ambroxol film composition is simple to process, has a high drug loading, and has good drug content uniformity, making it a promising market.

This invention belongs to the field of organic synthesis technology and provides a method for preparing a key intermediate of ambroxol hydrochloride. The method includes the following steps: methyl 2-aminobenzoate reacts with a brominating reagent under the action of an initiator to generate methyl 2-amino-3,5-dibromobenzoate via a bromination reaction; subsequently, methyl 2-amino-3,5-dibromobenzoate is reduced to 2-amino-3,5-dibromobenzyl alcohol in a reduction system; finally, under the action of an oxidizing agent, 2-amino-3,5-dibromobenzyl alcohol is further oxidized to form the target compound 2-amino-3,5-dibromobenzaldehyde. The optimized process has mild reaction conditions, conforms to green and environmentally friendly principles, significantly improves route safety, uses inexpensive and readily available raw materials, and achieves high product yield and purity, making it suitable for industrial production.

This invention belongs to the field of pharmaceutical formulation technology, specifically relating to an ambroxol hydrochloride inclusion complex, its formulation, and its uses. This invention utilizes inclusion complex technology and preferentially selects β-cyclodextrin and sodium cyclolactone as inclusion materials to prepare an ambroxol hydrochloride inclusion complex with high drug loading, high encapsulation efficiency, and high stability. Furthermore, this complex is combined with pharmaceutically acceptable excipients to formulate ambroxol hydrochloride tablets, solving the problem of ambroxol hydrochloride easily generating related substances under aerobic and light-exposed conditions, thus improving the stability of ambroxol hydrochloride tablets.

The invention belongs to the field of bronchial asthma medicines, and particularly discloses an aerosol inhalation solution for treating bronchial asthma as well as a preparation method and application of the aerosol inhalation solution. The aerosol inhalation solution is prepared from the following components in concentration: 1 to 5 mg / mL of terbutaline sulfate, 2 to 4 mg / mL of tremella polysaccharide, 1.5 to 3 mg / mL of glutathione, 2 to 6 mg / mL of a mucus regulator or a discharge promoting agent, sodium hyaluronate, astaxanthin and a pH regulator. Preferably, the mucus conditioning agent or the cleanup promoting agent is ambroxol hydrochloride, and further, the pH conditioning agent is selected from one of hydrochloric acid, acetic acid-sodium acetate and citric acid-sodium citrate; preferably, the sodium hyaluronate is modified sodium hyaluronate; in view of the defect that terbutaline sulfate is not stable enough, the terbutaline sulfate is reasonably matched, so that the stability of a solution is improved, impurities in the solution are reduced, and the atomization performance is improved.

1. Name of the product of this design: Pharmaceutical packaging box (Ambroxol Hydrochloride Oral Solution). 2. Purpose of this design product: This design is used for pharmaceutical packaging. 3. The key design points of this product are the combination of shape, pattern and color. 4. The picture or photo that best illustrates the design points: three-dimensional picture. 5. The design for which protection is sought includes color.

The invention discloses ambroxol hydrochloride sustained-release powder and a preparation method thereof. The method comprises the following steps: S1, mixing ambroxol hydrochloride and meso-porous silicon according to a mass ratio of 1: (0.8-1.5), stirring for 5-6 hours, and drying to obtain drug-loaded meso-porous silicon; s2, mixing the drug-loaded meso-porous silicon and a sustained-release material according to a mass ratio of 1: (5.5-7), dissolving, and coating to obtain skeleton powder containing the drug-loaded meso-porous silicon; s3, embedding the skeleton powder containing the drug-loaded meso-porous silicon and a wax material according to a mass ratio of 1: (2-3) to obtain prefabricated ambroxol hydrochloride sustained-release powder; and S4, adding a flavoring agent, and mixing to obtain the ambroxol hydrochloride sustained-release powder. The ambroxol hydrochloride sustained-release powder can be slowly and stably released by combining a plurality of sustained-release technologies, so that the medicine taking frequency of children is reduced, and the medication compliance is improved.

1. The name of the design product: packaging box (ambroxol hydrochloride oral solution). 2. The use of the design product: for product packaging. 3. The design points of the design product: in the combination of shape and pattern. 4. The picture or photo that best indicates the design points: front view.

1. The name of the design product: packaging box (ambroxol hydrochloride oral solution). 2. The use of the design product: for product outer packaging. 3. The design points of the design product: in the combination of shape and pattern. 4. The picture or photo that best indicates the design points: unfolded state reference drawing.

The invention relates to the technical field of pharmacy, in particular to a compound roxithromycin composition and a preparation method thereof. The compound roxithromycin composition is prepared from the following raw material components: a roxithromycin compound and an ambroxol hydrochloride compound, wherein the roxithromycin compound is obtained by treating roxithromycin with a coating material; the ambroxol hydrochloride compound is obtained by treating ambroxol hydrochloride with a coating material; according to the compound roxithromycin composition and the preparation method thereof, fluidized bed equipment is adopted for treating raw materials, a film coating material is prepared into suspension liquid, ambroxol hydrochloride is wrapped by a compact film formed in a fluidized state, and bitter taste is well covered; and meanwhile, the problem of bitter taste diffusion caused in production is solved, and industrial production is favorably realized.

The invention relates to a compound tilmicosin ambroxol temperature-sensitive gel and a preparation method thereof, and belongs to the technical field of veterinary pharmaceutical preparations. The compound tilmicosin and ambroxol temperature-sensitive gel disclosed by the invention is prepared from the following components in 100 mL: 7 to 10 g of tilmicosin phosphate, 0.5 to 1.5 g of ambroxol hydrochloride, 0.5 to 1.0 g of a preservative, 15 to 20 g of poloxamer, 1.0 to 1.5 g of chitosan, 0.1 to 0.15 g of stevioside, 10 to 12 mL of a tragacanth gum compound and the balance of a phosphate buffer solution. The compound tilmicosin ambroxol temperature-sensitive gel prepared by the invention can be used for treating respiratory system diseases of animals such as dogs, cats and the like caused by sensitive pathogenic bacteria in a nasal dripping manner; the tilmicosin and ambroxol compound can improve the animal medication compliance, and improve the in-vivo continuous action time and bioavailability of tilmicosin and ambroxol.